Advertisement
Document › Details
ERS Genomics Ltd.. (12/13/18). "Press Release: ERS Genomics and Lonza Enter into CRISPR/Cas9 Technology Licensing Deal". Dublin.
ERS Genomics Limited and Lonza Pharma & Biotech announced today a license agreement to provide Lonza with access to ERS Genomics’ CRISPR/Cas9 genome editing technology patents. Lonza will have the ability to utilize CRISPR/Cas9 in its bioproduction products and services and also for use in induced pluripotent stem cells (iPSC) for research applications.
“Lonza is the world’s leading contract manufacturing organization of biologics and we are thrilled that they have chosen to use CRISPR/Cas9 to enhance their capabilities,” commented Eric Rhodes, CEO of ERS Genomics. “We see tremendous potential for the use of gene editing to enhance the manufacturing of biologics and I expect Lonza will certainly be leading the way.”
Financial details of the agreement were not disclosed.
ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; livestock; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.
Contact ERS Genomics:
MacDougall Biomedical Communications
Mario Brkulj or Kara Mazey
Direct: +49 89 2420 9345 or +1 781 235 3060
E-Mail: ersgenomics@macbiocom.com
Record changed: 2023-06-05 |
Advertisement
More documents for ERS Genomics Ltd.
- [1] ERS Genomics Ltd.. (3/26/24). "Press Release: Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration". Dublin....
- [2] ERS Genomics Ltd.. (3/13/24). "Press Release: Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement". Tokyo & Dublin....
- [3] Empyrean Neuroscience, Inc.. (10/18/22). "Press Release: Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders". New York, NY & Cambridge....
- [4] ERS Genomics Ltd.. (8/17/21). "Press Release: ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement". Dublin & Coralville, IA....
- [5] ERS Genomics Ltd.. (6/1/21). "Press Release: Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third". Dublin....
- [6] ERS Genomics Ltd.. (3/3/21). "Press Release: ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical". Dublin....
- [7] ERS Genomics Ltd.. (3/1/21). "Press Release: ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development". Dublin....
- [8] ERS Genomics Ltd.. (2/16/21). "Press Release: ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement". Dublin & Barcelona....
- [9] ERS Genomics Ltd.. (12/1/20). "Press Release: Vivlion GmbH Signs Worldwide License Agreement With ERS Genomics for CRISPR/Cas9 Patent Portfolio". Dublin & Frankfurt/M.....
- [10] ERS Genomics Ltd.. (10/14/20). "Press Release: ERS Genomics Announces agreement with Fasmac to Commercialize CRISPR/Cas9 Research Reagents in Japan". Dublin & Kanagawa....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top